Nyumbani › Leukemia ya Lymphoblastic ya Ghafla › Washington › Seattle
Majaribio ya kliniki ya Leukemia ya Lymphoblastic ya Ghafla katika Seattle, WA
Masomo 21 ya Leukemia ya Lymphoblastic ya Ghafla yanatafuta washiriki katika vituo vya Seattle na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.
Maandishi rasmi ya utafiti (Kiingereza)
Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Inaajiri
- Seattle Children's, University of Washington, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
InaajiriUtafiti wa uchunguziWajitolea wenye afya wanakaribishwa
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- na zaidi ya 1
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
InaajiriHatua 1
- Fred Hutchinson Cancer Center, Seattle
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
InaajiriHatua 2
- Seattle Children's Hospital, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
InaajiriHatua 1/2
- Seattle Children's Hospital, Seattle
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
InaajiriUtafiti wa uchunguzi
- Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Seattle
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
InaajiriHatua 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
InaajiriHatua 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Multicenter HomeVENT: Home Values and Experiences Navigation Track
InaajiriWajitolea wenye afya wanakaribishwa
- Seattle Childrens Hospital, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
InaajiriUtafiti wa uchunguzi
- Fred Hutchinson Cancer Research Center, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
InaajiriHatua 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
InaajiriHatua 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
InaajiriHatua 2Wajitolea wenye afya wanakaribishwa
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
InaajiriHatua 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
InaajiriUtafiti wa uchunguzi
- Seattle Children's Hospital, Seattle
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
InaajiriHatua 3
- Ascentage Investigative Site #1806, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
InaajiriHatua 2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
InaajiriHatua 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
InaajiriHatua 1
- Fred Hutchinson Cancer Research Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
InaajiriHatua 1
- Fred Hutchinson Cancer Center, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
InaajiriHatua 1
- Seattle Children's Hospital, Seattle
Majaribio ya Leukemia ya Lymphoblastic ya Ghafla katika miji mingine
- Houston, TXUtafiti 28
- New York City, NYUtafiti 24
- Baldwin Park, CAUtafiti 21
- Chicago, ILUtafiti 19
- Atlanta, GAUtafiti 19
- Memphis, TNUtafiti 16
- Philadelphia, PAUtafiti 16
- Washington, DCUtafiti 16
- Boston, MAUtafiti 15
- Los Angeles, CAUtafiti 14
- Durham, NCUtafiti 13
- Mountain View, CAUtafiti 13
Masomo mengine katika Seattle
- Saratani ya Mapafu Isiyo na Selu NdogoUtafiti 53
- Saratani (aina zote)Utafiti 49
- Saratani ya ProstateUtafiti 42
- Leukemia ya Myeloid ya GhaflaUtafiti 40
- Saratani ya MatitiUtafiti 39
- Saratani ya MetastasiUtafiti 39
- Kansari ya kolorektaliUtafiti 34
- Saratan ya MapafuUtafiti 33
- Kansari ya MayaiUtafiti 30
- Multiple MyelomaUtafiti 22
- Sindromu za MyelodysplasticUtafiti 21
- Saratani ya MkojoUtafiti 21
Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.